Antibodies to human IL-22
US8182817B2 · kind B2 · utility
1Cited by
18References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 29, 2010 |
| Grant date | May 22, 2012 |
| Priority date | — |
| Expiry date | Sep 19, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.